-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
November 2, 2022 - Twist Bioscience Corporation (NASDAQ: TWST) is a company
that uses its silicon-based platform to deliver high-quality synthetic DNA to help customers succeed.
Illumina Corporation (NASDAQ: ILMN) is a global leader in
DNA sequencing and microarray technology.
The two companies today announced a partnership to make the joint Twist Bioscience® for Illumina Exome 2.
0 Plus portfolio available to more customers for Illumina® sequencers designed to advance disease research
.
Joydeep Goswami, Chief Strategy and Corporate Development Officer and Interim Chief Financial Officer of Illumina, said, "The collaboration with Twist brings a combination that performs optimally in sequencing preparation, furthering Illumina's mission
to transform disease research.
The Exome 2.
0 Plus combination has high uniformity and low off-target rates and excellent coverage, which makes it a market-leading exome portfolio, and we are excited to bring it to market
with Illumina products.
" ”
Under the terms of the agreement, Twist will produce the Exome 2.
0 Plus combo under the Illumina and Twist brands, which will be sold
by Illumina.
The Exome 2.
0 Plus portfolio provides Twist's latest set of protein-coding content, disease-associated variants, and non-coding variants
relevant to research applications.
High homogeneity and target rates as well as low loss and repeat read rates allow Illumina to maximize coverage of the target sequence with very few
wasted readings.
Illumina will sell the Exome 2.
0 Plus combination and Illumina's DNA Prep with Enrichment as a companion library preparation and exome enrichment protocol for research applications
.
Dr.
Emily M.
Leproust, CEO and co-founder of Twist Bioscience, said, "Incredible advances have been made in genomics and next-generation sequencing over the past decade, with both Illumina and Twist becoming leaders
in the field.
Together, we are able to provide the best solutions to a wider range of customers and benefit more people from our testing capabilities
.
”
About Twist Bioscience
Twist Bioscience is a leading and fast-growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform
to industrialize bioengineering.
The platform's core patented technology opens up a new way to
make synthetic DNA by "writing" DNA on a silicon chip.
Twist is leveraging its unique technology to manufacture a wide range of synthetic DNA-based products, including synthetic genes, next-generation sequencing (NGS) preparation tools, and antibody libraries
for drug discovery and development.
Twist also seeks longer-term opportunities
in the digital storage of DNA data and the exploration of biologics.
Twist manufactures products in a wide range of industries
, including healthcare, industrial chemicals, agriculture, and academic research.
Legal Statements for Forward-Looking Statements
This press release contains forward-looking statements
.
All statements other than historical facts, including, but not limited to, statements regarding the Exome 2.
0 Plus combination being able to maximize coverage of the target sequence with minimal wasted readings, are forward-looking statements
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that reflect management's current beliefs and expectations 。 Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause Twist Bioscience's actual results, performance or achievements to differ materially from
any future results, performance or achievements expressed or implied by the forward-looking statements 。 These risks and uncertainties include, among others, the ability to attract new customers and retain and increase sales of existing customers; Risks and uncertainties that rapidly changing technologies and broad competition in the field of synthetic biology may make the products being developed by Twist Bioscience obsolete or uncompetitive; the risk of a third party alleging that Twist Bioscience infringes patent and proprietary rights or seeks to invalidate its patents or proprietary rights; and the risks
that Twist Bioscience's proprietary rights may not be sufficient to protect its technology.
For a further description of the risks and uncertainties that could cause actual results to differ from these forward-looking statements, as well as risks related to Twist Bioscience's general business, please see the risk factors set forth in Twist Bioscience's Quarterly Report 10-Q filed with the Securities and Exchange Commission on August 8, 2022, and subsequent
filings with the SEC 。 Any forward-looking statements contained in this press release speak only as of the date of this press release, and Twist Bioscience expressly undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise
.
